Details for Patent: 9,649,318

Which drugs does patent 9,649,318 protect, and when does it expire?

Patent 9,649,318 protects VIVLODEX and is included in one NDA.

This patent has sixteen patent family members in sixteen countries.

Summary for Patent: 9,649,318

Title:	Formulation of meloxicam
Abstract:	Unit dosage forms of meloxicam containing either 5 mg or 10 mg of meloxicam that provide effective pain relief and have desirable pharmacokinetic properties are described. The unit dosage forms can provide pain relief when a single unit dose is administered to a patient and useful for treating pain such as osteoarthritis pain at a relatively low systemic exposure to meloxicam.
Inventor(s):	Bosch; H. William (Bryn Mawr, PA)
Assignee:	iCeutica Pty Ltd. (Balcatta WA, AU)
Application Number:	14/974,108
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 9,649,318
Patent Claim Types: see list of patent claims	Composition; Formulation; Dosage form;

Drugs Protected by US Patent 9,649,318

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Iceutica Operations	VIVLODEX	meloxicam	CAPSULE;ORAL	207233-001	Oct 22, 2015		DISCN	Yes	No			Y
Iceutica Operations	VIVLODEX	meloxicam	CAPSULE;ORAL	207233-002	Oct 22, 2015		DISCN	Yes	No			Y

International Family Members for US Patent 9,649,318

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Australia	2015274838
Brazil	112016027435
Canada	2951383
China	107073010
Eurasian Patent Organization	201692392